NEW YORK (GenomeWeb) – With $10 million in recent funding, Talis Biomedical is developing a point-of-care, sample-to-answer platform that incorporates a digital microfluidic technology called SlipChip.

The funding will also support development of pathogen identification and antibiotic susceptibility testing (AST) for bloodstream infections and for chlamydia and gonorrhea, the company said.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.